Noncolorectal Gastrointestinal Cancer Journal Articles

• Incidence and Mortality of HBV and HCV, Cirrhosis and HCC This article provides an update on the global incidence and mortality rates for these liver diseases. How have they changed in recent years?
  Journal of Viral Hepatitis, May 23, 2022
• Safety of IV Golimumab in RA, PsA, and AS A pooled analysis of data from three trials provides insight into the safety profile of IV golimumab for the treatment of these rheumatologic conditions.
  Arthritis Research & Therapy, May 18, 2022
• Risk of Hepatic and Extrahepatic Cancer in NAFLD This study investigated the risk of hepatic and extrahepatic cancer in patients with NAFLD compared to the general population.
  Liver International, May 16, 2022
• Medicaid Restriction Removal Increased HCV Treatment Rates Access to treatment improved after Medicaid-imposed restrictions were removed, but more policy changes are needed to address remaining disparities.
  Journal of Viral Hepatitis, May 16, 2022
• Adherence to the DASH Diet and NAFLD Is the DASH (Dietary Approaches to Stop Hypertension) diet effective at lowering risk of NAFLD?
  Liver International, May 09, 2022
• Differentiating Focal Liver Lesions: ICC and HCC Review the use of contrast-enhanced magnetic resonance imaging as an important diagnostic tool in the evaluation of indeterminate liver lesions.
  Applied Radiology, April 26, 2022
• Incidence of HCV Related HCC in the Era of IFN-free Therapies This study examined trends over time of HCV-associated hepatocellular carcinoma. How has incidence changed since the introduction of IFN-free therapies?
  Liver International, April 25, 2022
• HCV Cascade of Care Among People Living With HIV This study characterized the HCV care cascade among people living with HIV in New South Wales, comparing HCV testing and treatment uptake between pre- and post-introduction of DAAs in Australia.
  Journal of Viral Hepatitis, April 25, 2022
• Integrating HCV Screening of Baby Boomers at a Hospital ED This paper details the implementation of an opt-in HCV screening program for baby boomers presenting to a community hospital emergency department.
  Journal of Viral Hepatitis, April 18, 2022
• Tenofovir vs. Entecavir Therapy in HBV: Long-term Renal Safety Do tenofovir and entecavir differ in their long-term impact on renal function in patients with hepatitis B?
  Journal of Viral Hepatitis, April 11, 2022
• Chronic Hepatitis D--What Is Changing? Several new approaches to hepatitis D virus therapy have been explored in recent years. Review these advances and novel therapeutic options for HDV in this paper.
  Journal of Viral Hepatitis, April 04, 2022
• Hepatitis D Hospitalizations in the U.S.: 2010-2018 A new study provides insight into the hospitalization rates of hepatitis D in the U.S. and the various characteristics of these patients.
  Journal of Viral Hepatitis, March 31, 2022
• Prognosis of Patients With MAFLD by Non-invasive Methods Can non-invasive methods accurately predict global and liver-related mortality and morbidity in patients with MAFLD?
  Alimentary Pharmacology & Therapeutics, March 29, 2022
• Glycosylated 4-methylumbelliferone as Targeted Therapy for HCC This study found that glycosylation of 4MUR can improve its selectivity to tumor cells and may potentially be an effective targeted therapy for hepatocellular carcinoma.
  Liver International, March 28, 2022
• Liver-related and Extrahepatic Events in Patients With NAFLD This study evaluated the probability of developing liver-related events and extrahepatic events, considered as competing risks, in patients with NAFLD, stratified by fibrosis stage.
  Alimentary Pharmacology & Therapeutics, March 24, 2022
• Artificial Intelligence in the Diagnosis of Esophageal Diseases This review summarizes and evaluates the latest evidence for the use of AI in the diagnosis of both malignant and benign esophageal diseases.
  Alimentary Pharmacology & Therapeutics, March 22, 2022
• Long-Term Prognosis in Alcohol-related Liver Disease or NAFLD Metabolic syndrome and alcohol use frequently co-exist. This study assessed survival in patients with NAFLD according to alcohol use and ALD according to the presence of metabolic syndrome.
  Liver International, March 21, 2022
• Epidemiological and Clinical Features of MAFLD and NAFLD The transition from the nomenclature NAFLD to MAFLD remains heavily debated. How do their epidemiological and clinical features compare, and is MAFLD the preferable terminology?
  Liver International, March 14, 2022
• Hepatocellular Carcinoma in Noncirrhotic and Cirrhotic livers What are the clinicopathologic differences between hepatocellular carcinoma arising in noncirrhotic and cirrhotic livers?
  American Journal of Clinical Pathology, March 09, 2022
• Cancer Risk in Patients With Autoimmune Hepatitis Do persons with autoimmune hepatitis have an increased risk of hepatic or extrahepatic cancers compared with the general population and siblings?
  American Journal of Epidemiology, March 09, 2022